U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
1032 articles with Allergan, Inc.
Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)
Interim analysis of relapse prevention study suggests the primary endpoint will not be met
Allergan plc announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts.
Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C.
Allergan plc announced that its data will be featured during the 2019 American Academy of Dermatology Annual Meeting in Washington D.C. March 1-5, 2019.
2/22/2019Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more.
Sixth New Director Since 2017 as Part of Allergan's Transformation from a Generic to a Branded Biopharmaceutical Company
Allergan plc today issued the following statement from its Board of Directors in response to a public shareholder letter.
Allergan plc, a leading global biopharmaceutical company, announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY.
According to a real estate analysis, the per-square-foot costs in Kendall Square increased $18 in 2018.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allergan plc. of Class Action Lawsuit and Upcoming Deadline - AGN
Pomerantz LLP announces that a class action lawsuit has been filed against Allergan plc. and certain of its officers.
Full-Year 2018 GAAP Net Revenues of $15.8 Billion; Q4 2018 GAAP Net Revenues of $4.1 Billion
New BOTOX® Cosmetic (onabotulinumtoxinA) "Own Your Look" Campaign Brings Fresh Face To Trusted Brand
Campaign targets new generation of users with an updated, modern approach
First Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share to be Paid on March 15, 2019; Record Date of February 15, 2019
Amgen and Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar candidate to RITUXAN® (rituximab), compared to rituximab in patients with moderate-to-severe rheumatoid arthritis.
Amgen and Allergan announced positive top-line results from a Phase I/Phase III trial of their biosimilar candidate, ABP 798, to Genentech and Biogen’s Rituxan (rituximab).
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
ALLERGAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan plc. - AGN
Kahn Swick & Foti, LLC and Charles C. Foti, Jr., remind investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc. (NYSE: AGN), if they purchased the Company’s shares between February 24, 2017, and December 19, 2018
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
Television Personality Named as Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment*
Tuesday, January 8, was another busy day in San Francisco for the JP Morgan Healthcare Conference. One interesting sideline was the idea that the current government shutdown could complicate some deals.
In 2015, shares of Allergan were trading at $331.15. This morning, the price of that stock is more than half that price, $145.60 following a 2.2 percent increase after the first day of the J.P. Morgan Healthcare Conference.